Inhibamet 12.5/1000 mg, 30 tablets

Trade Name:

Inhibamet 12.5/1000 mg

Composition

Each tablet contains:

Alogliptin 12.5 mg

Metformin hydrochloride 1000 mg

Properties

Inhibamet is a combination of two hypoglycemic agents with complementary and different mechanisms of action designed to improve glycemic control in patients with type 2 diabetes mellitus (T2DM): alogliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), and metformin, a member of the biguanide class .

Indications

Type 2 diabetes mellitus in adults aged 18 years and older to improve glycemic control in addition to diet and exercise.

Dosage and administration

The drug is taken orally.

Assign 1 tab. 2 times / day simultaneously with food intake in order to reduce unwanted reactions from the gastrointestinal tract. The tablets should be swallowed whole, without chewing, with water.

The dose of the drug is selected individually.

Contraindications

Hypersensitivity to alogliptin or metformin or any of the excipients.type 1 diabetes;

diabetic ketoacidosis, diabetic precoma, coma;

moderate or severe renal failure (creatinine clearance less than 60 ml / min);

Side effects

Infectious and parasitic diseases: often — infections of the upper respiratory tract, nasopharyngitis.

From the nervous system: often — headache, taste disturbance — metallic taste in the mouth (for metformin).

From the gastrointestinal tract: very often (for metformin) — abdominal pain, diarrhea, loss of appetite, nausea, vomiting; often — abdominal pain, gastroesophageal reflux disease, gastroenteritis, diarrhea, vomiting, gastritis.

Storage

Store at a temperature not exceeding 30°C.

Package:

The cardboard box contains 1, 2 or 3 blisters of 10 tablets, paper leaflet.